ArticleJournal of gynecologic oncology2024

Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis.

Youwen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.